Organisation of neoplastic haematopathology services: a UK perspective

被引:5
作者
Jack, A [1 ]
机构
[1] Leeds Teaching Hosp, NHS Trust, Dept Haematol, Haematol Malignancy Diagnost Serv, Leeds LS1 3EX, W Yorkshire, England
关键词
haematopathology; hematopathology; flow cytometry; FISH; lymphoma; leukaemia;
D O I
10.1080/00313020500368360
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The diagnosis of haematological malignancies has begun to emerge as a distinct pathological discipline in the United Kingdom. This has been driven by the recommendation of the National Institute for Clinical Excellence that diagnosis of leukaemia and lymphoma should take place in a specialist laboratory and in most cases this should be organised on a regional basis. The reason for this guidance was the perception that there was a considerable level of diagnostic inaccuracy and that this could be improved by better integration of the currently available technologies. This is one of a number of major changes in the way that services to patients are being delivered, all of which are centred on the development of multidisciplinary teams responsible for the provision of local services. The introduction of the WHO classification of haematological malignancy provides a structure for the development of integrated haemtopathology laboratories, with its emphasis on definition of disease entities based on clinical, morphological, phenotypical and molecular features. This means that these diagnostic modalities can be used systematically and in parallel to provide effective cross validation of a diagnosis. One of the challenges raised by this approach is the selection of the most informative panels of investigations both at presentation and subsequent follow up from the wide range of options that are now available. The introduction of specialist haematopathology services in the United Kingdom has highlighted a number of scientific and organisational issues that in time may have a wider impact on diagnostic laboratories in general. These include the relationship between size and cost effectiveness and the future role of clinical scientists and medically trained pathologists. Integrated laboratories of the type being developed challenge the prevailing model for delivery of pathological services in the United Kingdom, which is based around the traditional pathology disciplines. These speciality boundaries will become less relevant as long established diagnostic techniques are replaced by the new generation of diagnostic technologies and it is important to establish frameworks of service delivery that can deploy these developments for the benefit of patients.
引用
收藏
页码:479 / 492
页数:14
相关论文
共 78 条
[1]   Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance [J].
Alcalay, M ;
Tiacci, E ;
Bergomas, R ;
Bigerna, B ;
Venturini, E ;
Minardi, SP ;
Meani, N ;
Diverio, D ;
Bernard, L ;
Tizzoni, L ;
Volorio, S ;
Luzi, L ;
Colombo, E ;
Lo Coco, F ;
Mecucci, C ;
Falini, B ;
Pelicci, PG .
BLOOD, 2005, 106 (03) :899-902
[2]   Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].
Alizadeh, AA ;
Eisen, MB ;
Davis, RE ;
Ma, C ;
Lossos, IS ;
Rosenwald, A ;
Boldrick, JG ;
Sabet, H ;
Tran, T ;
Yu, X ;
Powell, JI ;
Yang, LM ;
Marti, GE ;
Moore, T ;
Hudson, J ;
Lu, LS ;
Lewis, DB ;
Tibshirani, R ;
Sherlock, G ;
Chan, WC ;
Greiner, TC ;
Weisenburger, DD ;
Armitage, JO ;
Warnke, R ;
Levy, R ;
Wilson, W ;
Grever, MR ;
Byrd, JC ;
Botstein, D ;
Brown, PO ;
Staudt, LM .
NATURE, 2000, 403 (6769) :503-511
[3]   Blast count and cytogenetics correlate and are useful parameters for the evaluation of different phases in chronic myeloid leukemia [J].
Bacher, U ;
Kern, W ;
Schnittger, S ;
Hiddemann, W ;
Schoch, C ;
Haferlach, T .
LEUKEMIA & LYMPHOMA, 2005, 46 (03) :357-366
[4]   Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information [J].
Bacher, U ;
Haferlach, T ;
Kern, W ;
Hiddemann, W ;
Schnittger, S ;
Schoch, C .
ANNALS OF HEMATOLOGY, 2005, 84 (04) :250-257
[5]  
Banham AH, 2005, CLIN CANCER RES, V11, P1065
[6]   Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome [J].
Barrans, SL ;
Fenton, JAL ;
Banham, A ;
Owen, RG ;
Jack, AS .
BLOOD, 2004, 104 (09) :2933-2935
[7]   The detection of t(14;18) in archival lymph nodes -: Development of a fluorescence in situ hybridization (FISH)-based method and evaluation by comparison with polymerase chain reaction [J].
Barrans, SL ;
Evans, PAS ;
O'Connor, SJM ;
Owen, RG ;
Morgan, GJ ;
Jack, AS .
JOURNAL OF MOLECULAR DIAGNOSTICS, 2003, 5 (03) :168-175
[8]  
Barrans SL, 2003, CLIN CANCER RES, V9, P2133
[9]   Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma [J].
Barrans, SL ;
Carter, I ;
Owen, RG ;
Davies, FE ;
Patmore, RD ;
Haynes, AP ;
Morgan, GJ ;
Jack, AS .
BLOOD, 2002, 99 (04) :1136-1143
[10]   Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma [J].
Barrans, SL ;
O'Connor, SJM ;
Evans, PAS ;
Davies, FE ;
Owen, RG ;
Haynes, AP ;
Morgan, GJ ;
Jack, AS .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (02) :322-332